
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is attractive because 3Q revenue of $206.7M and adj. EPS of $0.14 beat expectations, with U.S. revenue of about $197.5M offsetting softer OUS sales and gross margin reaching 86.0% on a favorable Inspire V mix. The company also narrowed FY26 revenue guidance to $850M-$860M while lifting the midpoint of adj. EPS guidance to $1.20-$1.40, suggesting management sees the current coding and reimbursement headwinds easing rather than worsening. Investor confidence is further supported by new CPT codes effective January 1, 2028, which should reduce procedure-coding confusion, improve visibility into the 2027 trajectory, and help support continued adoption in the still-nascent U.S. surgical OSA market.
Bears say
Inspire Medical Systems is facing a negative outlook because its recent modest 3Q revenue and EPS beat was driven mainly by about $5M of U.S. upside, while softer international performance and a guidance cut earlier in the year reinforced concerns that growth is slowing. Management’s expectation for a return to growth in 2027 does not offset near-term pressure from coding and reimbursement frictions, which are limiting profitability and leaving less conviction that the company can consistently exceed guidance. Even with a potential new Category I code by Jan 1 2028 and longer-term support from Inspire 5, structural headwinds such as capacity constraints, GLP1-driven TAM pressure, competition, and launch delays could keep growth constrained.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Inspire Medical Systems Inc (INSP) Forecast
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares